Detailed Agenda

Thursday, September 12, 2019

PM

1:00 – 1:15 – Introduction by ISHEN President and the Organizing Committee, Introduction to the definition and classification of hepatic encephalopathy (HE)
Jasmohan S. Bajaj, MD, MSc, FACG

1:15 – 3:15 – Importance of HE and Potential Reversibility

Session Chairs:
Jasmohan S. Bajaj, MD, MSc, FACG
Kevin Mullen, MD

Clinical Sciences
1:15 – 1:30 – Impact of HE from a population perspective on the healthcare system
Elliott Tapper, MD

1:30 – 1:45 – Impact of HE on patients and caregivers, and role of irreversible cognitive defects
Puneeta Tandon, MD

Basic Sciences
1:45 – 2:00 – Pathophysiology of senescence with HE
Sharon DeMorrow, PhD

Translational
2:00 – 2:15 – Neuro-imaging of patients with HE and reversibility with therapy and transplant
Mark McPhail, MD

New Investigator/Oral Presentation
2:15 – 2:30 – Genetic fingerprint of hepatic encephalopathy risk in liver cirrhosis
Antonio Gil-Gomez

2:30 – 2:45 – Opioid Prescriptions Increase the Risk of Hepatic Encephalopathy in a National Cohort of Privately Insured Patients with Compensated Cirrhosis
Andrew W. Moon, MD, MPH

2:45 – 3:00 – Clinical Value of Asterixis in a Large Population of Well-Characterised Patients with Cirrhosis and Varying Degree of Hepatic Encephalopathy
Chiara Formetnin

Summation and Q&A
3:00 – 3:15
Kevin Mullen, MD

Break with Exhibits and Posters
3:15 – 3:30

3:30 – 5:15 – Pathogenesis of HE

Session Chairs:
Roger Butterworth, MD
Vincente Felipo, MD

Basic Sciences
3:30 – 3:45 – Impact of HE on brain in astrocytic, glial, microglial cells
Christopher Rose

3:45 – 4:00 – Impact of extra-cerebral factors (gut and muscle) in the pathogenesis of HE
Nathan Davies, PhD

4:00 – 4:15 – The contribution of the blood/brain barrier/choroid plexus in the pathology of HE
Radhakrishnan Jayakumar

Clinical Sciences
4:15 – 4:30 – Role of co-morbid conditions in the pathogensis of HE
Hendrik Vilstrup

Translational
4:30 – 4:45 – Ammonia: bridging the gap between pathogenesis and clinical application
Dominique Thabut

New Investigator/Oral Presentation
4:45 – 5:00 – Uncovering sex-based differences in a rat model of chronic liver disease and hepatic encephalopathy
Mariana M. Oliveira

Summation and Q&A
5:00 – 5:15
Roger Butterworth, MD

Attendee Dinner
6:00 – 8:00

Friday, September 13, 2019

AM

8:00 – 9:30 – Type A Hepatic Encephalopathy

Session Chairs:
Rajiv Jalan, MD
Peter Ott

Basic Sciences
8:00 – 8:15 – Recent updates in the role of neuro-inflammation in acute liver failure
Rajiv Jalan, MD

Clinical Sciences
8:15 – 8:30 – Novel treatment options for Type A HE
William Bernal

8:30 – 8:45 – Management of the brain in critical care settings
Todd Stravitz, MD

Translational
8:45 – 9:00 – Animal models of acute liver failure with focus on the brain
Nathan Davies, PhD

New Investigator/Oral Presentation
9:00 – 9:15 – Let7f Expression is Upregulated in the Frontal Cortex During Acute Liver Failure and Contributes to Hepatic Encephalopathy via Downregulation of IGF1 Expression
Elaina Williams

Summation and Q&A
9:15 – 9:30
Peter Ott

Break with Exhibits and Posters
9:30 – 9:45

9:45 – 12:00 – Challenges in the Diagnosis of HE

Session Chairs:
Jasmohan S. Bajaj, MD, MSc, FACG
Piero Amodio, MD

Clinical Sciences
9:45 – 10:00 – Covert HE vs. other forms of cognitive impairment
Mette Lauridsen

10:00 – 10:30 – Overt HE vs. other forms of confusion
Piero Amodio, MD

Basic Sciences
10:30 – 10:45 – Impact of inflammation as a mediator of changes in HE
Debbie L. Shawcross, MD, PhD

Translational
10:45 – 11:00 – Newer modalities: new biomarkers metabolomics
Nicolas Weiss, MD, PhD

11:00 – 11:15 – Newer modalities: Brain Imaging
Mark McPhail, MD

New Investigator/Oral Presentation
11:15 – 11:30 – Interaction of Pre-Dementia Mild Cognitive Impairment and Hepatic Encephalopathy in Elderly Patients with Cirrhosis: A Multi-Center Study
Jessie Xie

11:30 – 11:45 – Identifying Overt Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era: A Study to Validate Diagnostic Algorithms
Sophia Korovaichuk, MD

Summation and Q&A
11:45 – 12:00
Piero Amodio, MD

PM

Lunch
12:00 – 1:00

1:00 – 2:30 – Treatments for overt HE inpatient and outpatient

Session Chairs:
Sara Montagnese
Marsha Morgan

Basic Sciences
1:00 – 1:15 – Newer targets for overt HE therapies
Radha K. Dhiman

Clinical Sciences
1:15 – 1:30 – Overt HE inpatient management
Manuel Romero-Gomez

1:30 – 1:45 – Overt HE prevention of recurrence including combination therapies
BC Sharma

Translational
1:45 – 2:00 – Experience with newer therapies for overt HE (evaluation of current and ongoing trials)
Robert Rahimi, MD, MSCR

New Investigator/Oral Presentation
2:00 – 2:15 – Pharmacotherapies that Specifically Target Ammonia for the Prevention and Treatment of Hepatic Encephalopathy in Adults with Cirrhosis
Harry D. Zacharias, BSc, MBBS

Summation and Q&A
2:15 – 2:30
Marsha Morgan

Break with Exhibits and Posters
2:30 – 2:45

2:45 – 4:30 – Assessment of Cognitive Dysfunction

Session Chairs:
Jasmohan S. Bajaj, MD, MSc, FACG
BC Sharma

Basic Sciences
2:45 – 3:00 – Evaluation of cognitive dysfunction in animal models and relatability to human disease
Vincente Felipo, MD

Clinical Sciences
3:00 – 3:45
– Paper/pencil testing – Karin Weissenborn
– Neuro-physiological testing – Sara Montagnese
– Electronic interfaces – Cristina Ripoll

Translational
3:45 – 4:00 – Real-world application of tests and cost-effectiveness
Oliviero Riggio

New Investigator/Oral Presentation
4:00 – 4:15 – Assessment of cirrhotic patients with covert Hepatic Encephalopathy (HE) through the EncephalApp (Stroop-Test) based on Critical Flicker Frequency and PHES-Test
Rebecca Maria Neye

Summation and Q&A
4:15 – 4:30
Jasmohan S. Bajaj, MD, MSc, FACG

Junior Investigator Networking Cocktail Hour, Poster Viewing/Scoring
6:00 – 7:00

Evening Reception with DJ and Dancing
7:30 – 11:30

Saturday, September 14, 2019

AM

8:00 – 9:30 – Liver Transplant (LT)

Session Chairs:
Manuel Romero-Gomez
Simone Strasser

Basic Sciences
8:00 – 8:15 – Impact of immunosuppressive drugs on brain function
Nathan Davies, PhD

Clinical Sciences
8:15 – 8:30 – Priority listing for HE patients for LT
Elliott Tapper, MD

8:30 – 8:45 – Reversibility post-LT
Cristina Ripoll

Translational
8:45 – 9:00 – Using evidence to determine the extent of recovery
Dominique Thabut

New Investigator/Oral Presentation
9:00 – 9:15 – Hepatic Encephalopathy is reversible in the long-term after liver transplantation
Henning Pflugrad, MD

Summation and Q&A
9:15 – 9:30
Simone Strasser

Break with Exhibits and Posters
9:30 – 9:45

9:45 – 11:15 – Gut-Brain Axis

Session Chairs:
Hendrik Vilstrup
Jasmohan S. Bajaj, MD, MSc, FACG

Basic Sciences
9:45 – 10:00 – Components of gut-brain axis in healthy and diseased situations
Debbie L. Shawcross, MD, PhD

Clinical Sciences
10:00 – 10:15 – Intestinal barrier and systemic inflammation in cirrhosis
Vishal Patel, MD

Translational
10:15 – 10:30 – Newer options to manage and treat HE via the gut
Jasmohan S. Bajaj, MD, MSc, FACG

New Investigator/Oral Presentation
10:30 – 10:45 – PROFIT: PROspective, randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis interim analysis
Charlotte Woodhouse, MBBS

10:45 – 11:00 – Cognitive Improvement after Capsular Fecal Microbial Transplant in Hepatic Encephalopathy is Associated with Changes in Microbial Function and Inflammation
Chathur Acharya, MBBS

Summation and Q&A
11:00 – 11:15
Jasmohan S. Bajaj, MD, MSc, FACG

Andy Blei Lecture
11:15 – 12:00
Piero Amodio, MD

PM

Lunch
12:00 – 1:00

1:00 – 3:00 – Brain dysfunction prior to cirrhosis development

Session Chair:
Mark Swain
Puneeta Tandon

Basic Sciences
1:00 – 1:15 – Impact of systemic inflammation, HCV and obesity on brain
Nicolas Weiss, MD, PhD

Clinical Sciences
1:15 – 1:30 – Effect of viral hepatitis and fatty liver on brain function
Mark McPhail, MD

1:30 – 1:45 – Effect of cholestatic liver diseases and alcohol on brain function
Mark Swain

Translational
1:45 – 2:00 – Mediators of brain dysfunction in pre-cirrhotic liver disease
Puneeta Tandon

New Investigator/Oral Presentation
2:00 – 2:15 – The role of monocarboxylate transporter-1 and lactate metabolism on the development of cognitive deficits during NAFLD
Anna Hadjihambi

2:15 – 2:30 – Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion
Peter Lykke Eriksen, MD, PhD

Summation and Q&A
2:30 – 2:45
Mark Swain

Break with Exhibits and Posters
2:45 – 3:15

3:15 – 4:45 – Current treatments for covert HE

Session Chairs:
Sara Montagnese
Radha Dhiman

Basic Sciences
3:15 – 3:30 – Role of inflammation, oxidative stress and its modulation
Christopher Rose

Clinical Sciences
3:30 – 3:45 – Gut based therapies
Oliviero Riggio

3:45 – 4:00 – Therapies focused outside the gut
Gerard Kircheis, MD

Translational
4:00 – 4:15 – Modulators of treatment response
Andres Duarte-Rojo, MD

New Investigator/Oral Presentation
4:15 – 4:30 – Functional MRI – Evidence of a Treatment Effect of LOLA
Yasmin Pasha

Summation and Q&A
4:30 – 4:45
Radha Dhiman

Walking Tour of Williamsburg
5:00 – 6:00
(optional) 

Buffet Networking Dinner
6:30 – 8:00

Sunday, September 15, 2019

AM

7:30 – 9:00 – Patient-reported outcomes and role of Advanced Practitioners

Session Chair:
Elliott Tapper, MD
Hendrik Vilstrup

Clinical Sciences
7:30 – 8:15
– Role of PROs in HE – Elliott Tapper, MD
– Sleep alterations in cirrhosis and relationship with HE – Sara Montagnese
– Role of Allied Health Professionals: Nurses and Nurse Practitioners – HoChong Gilles
– Role of Allied Health Professionals: Dietary Interventions – Helen Vidot

Translational
8:15 – 8:30 – Impact of PROs on prognostication
Mette Lauridsen

New Investigator/Oral Presentation
8:30 – 8:45 – Traditional Prognostic Tools are Superior to Cognitive Testing and Stool Frequency as Predictors of Poor Outcomes in Cirrhotic Patients Admitted with Hepatic Encephalopathy
Patricia Pringle Bloom, MD

Summation and Q&A
8:45 – 9:00
Hendrik Vilstrup

Break with Exhibits and Posters
9:00 – 9:30

9:30 – 11:00 – It is not just the gut

Session Chairs:
Roger Butterworth, MD
Gerard Kircheis, MD

Basic Sciences
9:30 – 9:45 – Role of skeletal muscle in brain dysfunction
Debbie L. Shawcross, MD, PhD

9:45- 10:00 – Bile acids and the brain
Sharon DeMorrow, PhD

Clinical Sciences
10:00 – 10:15 – Exercise and brain function
Andres Duarte-Rojo, MD

Translational
10:15 – 10:30 – Ammonia scavengers and HE
Robert Rahimi, MD, MSCR

New Investigator/Oral Presentation
10:30 – 10:45 – The two-year outcome in patients with MHE and Sarcopenia on mortality and the development of OHE
Rohit Gupta, MBBS

Summation and Q&A
10:45 – 11:00
Roger Butterworth, MD

11:00 – 11:30 – HE management worldwide

Session Chairs:
Jasmohan S. Bajaj, MD, MSc, FACG
Sharon DeMorrow, PhD

Asia Pacific: China
11:00 – 11:15
Xu Jinghang

Latin America: Mexico
11:15 – 11:30
Alex Torre, MD

Pick up boxed lunch
11:30 – 11:35

11:35 – 2:15 – Consensus statements on OverT HE management, Covert HE management, and updated animal model analyses

Each session will have specific statements sent out at least 2 months prior to the meeting which will be collated and discussed during this meeting.

Program Adjourns
2:15